Cargando…

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

BACKGROUND: Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). MATERIALS AND METHODS: The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a fully enrolled (2012–2016), observational, prospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripathy, Debu, Brufsky, Adam, Cobleigh, Melody, Jahanzeb, Mohammad, Kaufman, Peter A., Mason, Ginny, O'Shaughnessy, Joyce, Rugo, Hope S., Swain, Sandra M., Yardley, Denise A., Chu, Laura, Li, Haocheng, Antao, Vincent, Hurvitz, Sara A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Breast Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011632/ https://www.ncbi.nlm.nih.gov/pubmed/32043771 http://dx.doi.org/10.1634/theoncologist.2019-0446

Ejemplares similares

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
por: Tripathy, Debu, et al.
Publicado: (2014)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
por: Cardoso, Fatima, et al.
Publicado: (2023)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
por: Kaufman, Peter A, et al.
Publicado: (2014)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients
por: van der Velden, Bas H. M., et al.
Publicado: (2018)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Invasive Colloid Carcinoma and the role of Ki-67 and HER2 – Two case reports
por: Patel, Sarvanand, et al.
Publicado: (2018)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
por: Chowdhary, Mudit, et al.
Publicado: (2019)

Syst
por: Vialettes, H
Publicado: (1971)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
por: Chien, A. Jo, et al.
Publicado: (2012)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
por: Miller, Kathy, et al.
Publicado: (2016)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells
por: DiScala, Molly, et al.
Publicado: (2020)

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
por: Goetz, Matthew P., et al.
Publicado: (2020)

The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China
por: Xie, Fei, et al.
Publicado: (2022)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
por: Soliman, Hatem, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ik8uigi82c2j062jj0q7jicmdq